Drug Trial Radar · NCT06521034
First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jul 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
124
Actual
Start
Jun 27, 2019
Primary completion
May 17, 2021
Study completion May 17, 2021
Sponsor
- Lead sponsor
- Yongchang ZhangAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
- First posted
- Jul 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
FHND-9041 capsule is a novel third-generation EGFR inhibitor targeting EGFR-sensitive mutations. This first-in-human study is a single-arm, multi-center, open-label, non-randomized Phase Ⅰ/II trial. It aims to evaluate the tolerability, safety, pharmacokinetics, and anti-tumor activity of FHND-9041 in patients with NSCLC harboring the EGFRT790M mutation, particularly those acquiring resistance to prior EGFR-TKI treatment. Additionally, the study seeks to determine the Recommended Phase II Dose (RP2D) of FHND-9041and assess its efficacy as a first-line treatment for patients with locally advanced or metastatic NSCLC harboring EGFR-sensitive mutations.
Conditions
- Non-small Cell Lung Cancer
- EGFR Gene Mutation
- EGFR-TKI Sensitizing Mutation
Interventions
FHND-9041Drug
In Phase I, using a "3+3" design, dose escalation and expansion studies were conducted at doses of 40, 80, 120 and 180 mg/day. At least 3 patients were enrolled in each dose arm, and no dose-limiting toxicities were observed. With a plateau observed at 120 mg/day, the 80 mg/d and 120mg/d groups were selected for dose expansion. The 80mg/d queue has expanded by 36 patients, and the 120mg/d queue has expanded by 39 patients. In Phase Ⅱ, after comprehensive analysis and consultation, at least 30 patients were enrolled according to the inclusion and exclusion criteria. 37 patients with locally advanced or metastatic EGFR-mutated NSCLC receiving first-line treatment were enrolled.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic Parameters of Maximum Serum Concentration (Cmax) after cycle 1Time frame: through study completion, an average of 1 year
- Pharmacokinetic Parameters Area Under the Concentration-Time Curve After Cycle 1Time frame: through study completion, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yongchang Zhang
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.